Cutaneous drug eruptions by current antiepileptics: Case reports and alternative treatment options

Clinical Neuropharmacology

Volumn 31, Issue 2, 2008, Pages 93-96

  Sahin, Sevki ^a,b   Comert, Asuman ^a   Akin, Ozlem ^a   Ayalp, Sunay ^a   Karsidag, Sibel ^a  

^a MALTEPE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Drug eruptions; Gabapentin; Lamotrigine; Leukocytoclastic vasculitis; TEN

Indexed keywords

ANTIHISTAMINIC AGENT; BOTULINUM TOXIN; CARBAMAZEPINE; CORTICOSTEROID; ETIRACETAM; GABAPENTIN; GLUCOCORTICOID; LAMOTRIGINE; VALACICLOVIR; VALPROIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; LEUKOCYTOCLASTIC VASCULITIS; MACULOPAPULAR RASH; MALE; MYOCLONUS SEIZURE; PAPULOVESICULAR RASH; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PURPURIC RASH; SKIN BIOPSY; TOXIC EPIDERMAL NECROLYSIS; VOMITING;

ADULT; AMINES; ANTIEMETICS; CYCLOHEXANECARBOXYLIC ACIDS; EPIDERMAL NECROLYSIS, TOXIC; EPILEPSY; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; TRIAZINES; VASCULITIS, HYPERSENSITIVITY;

EID: 41749090293     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31806ad6cb     Document Type: Article

References (16)

1. Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005;64:1134-1138.
2. Poon DY, Law NM. A case of cutaneous leukocytoclastic vasculitis associated with gabapentin. Singapore Med J 2003;44:42-44.
3. Crowson AN, Magro CM. Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin 1999;17:537-560.
4. Crowson AN, Brown TJ, Magro CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions. Am J Clin Dermatol 2003;4(6):407-428.
5. Wolff K, Johnson RA, Suurmond D. Miscellaneous Inflammatory Disorders. In: Wolff K, Johnson RA, Suurmond D, eds. Fitzpatrick's Color Atlas & Synopsis of Clinical Dermatology, 5th ed. USA: McGraw-Hill Companies; 2005:146-148.
6. Scheinfeld N. The role of gabapentin in treating diseases with cutaneous manifestations and pain. Int J Dermatol 2003;42:491-495.
7. Beydoun A. Postherpetic neuralgia: role of gabapentin and other treatment modalities. Epilepsia 1999;6:S51-S56.
8. Ragozzino MW, Melton LJ III, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine 1982;61:310-316.
9. Niv D, Maltsman-Tseikhin A. Postherpetic neuralgia: the never-ending challenge. Pain Pract 2005;5:327-340.
10. McKendrick MW, McGill JI, Wood MJ. Lack of effect of acyclovir on post herpetic neuralgia. BMJ 1989; 298:431.
11. Turk U, Ilhan S, Alp R, et al. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol 2005;28:161-162.
12. Stern RS, Chan HL. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol 1989;21: 317-322.
13. Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-96.
14. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Eng J Med 1994;19:1272-1285.
15. Messenheimer JA, Mullens EL, Giorgi L. Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998;18: 281-296.
16. Otoul C, Arrigo C, van Rijckevorsel K, et al. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005;28(2):72-78.